Comparative Pharmacology
Head-to-head clinical analysis: AXID versus PEPCID COMPLETE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXID versus PEPCID COMPLETE.
AXID vs PEPCID COMPLETE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive, reversible inhibition of histamine at H2-receptors on gastric parietal cells, reducing gastric acid secretion by blocking the H2-receptor-mediated activation of adenylate cyclase and subsequent cAMP production.
Famotidine competitively inhibits histamine at H2-receptors of gastric parietal cells, reducing gastric acid secretion. Calcium carbonate and magnesium hydroxide act as antacids to neutralize existing gastric acid.
300 mg orally once daily at bedtime or 150 mg orally twice daily. Max 300 mg/day.
One tablet (famotidine 10mg, calcium carbonate 800mg, magnesium hydroxide 165mg) orally once daily, taken 30 minutes before a meal that causes heartburn.
None Documented
None Documented
1.5-2.5 hours (prolonged in renal impairment: up to 4-5 hours if CrCl <20 mL/min)
2.5-3.5 hours (prolonged to 12-20 hours in severe renal impairment, CrCl <10 mL/min).
Renal (60% unchanged), biliary (30%), fecal (<10%)
Renal: 65-70% (famotidine unchanged); fecal: 30-35% (as metabolites). Biliary elimination is minimal (<5%).
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist